Melanocortin binding
The cyclic peptide acts as an agonist at several melanocortin receptors, including MC1R, MC3R and MC4R.
NXP / 08
Research profile
Melanotan II
10MGNonselective melanocortin-receptor agonist research peptide
Melanotan II is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone. Laboratory research uses it to examine melanocortin-receptor signalling across pigmentation, appetite and neuroendocrine pathways.
NEXPEP PRICE$79.00 AUDThe same current price shown throughout the Nexpep store.
Scientific context
What it does.
Melanotan II activates multiple melanocortin receptor subtypes rather than one selective target. Its broad receptor activity makes receptor-selective controls important when interpreting pigmentation, behavioural or metabolic assay results.
Mechanism map
How the research
model works.
Pigment-pathway signal
MC1R activation is associated with melanogenic signalling in pigment-cell models.
Central-pathway signal
MC3R and MC4R activity is studied in appetite, energy-balance and behavioural research models.
Study design
Research pairing
options.
These are experimental design concepts—not recommendations for human use, co-administration or dosing.
Vehicle control
Separates peptide-associated readouts from solvent and handling effects.
Match exposure time, matrix and sampling conditions.Receptor-selective comparator
Helps identify which melanocortin-receptor subtype contributes to an observed signal.
Use a predefined receptor and endpoint rather than assuming selectivity.Unstacked control
A single-agent arm provides the clearest interpretation of broad melanocortin activity.
Avoid adding other endocrine-active materials to the primary comparison.Interpretation controls
Important
limitations.
- Melanotan II is not approved by the TGA for therapeutic or cosmetic use.
- Early human research reported adverse effects including nausea, fatigue and somnolence.
- Identity, purity and receptor activity require analytical verification before research interpretation.
Evidence trail